Sara C. Shalin
High Impact
Professor
faculty
Department Chairs, College of Medicine
21 h-index
149 pubs
2,372 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Sara C. Shalin is a Professor in the Department of Pathology at the University of Arkansas for Medical Sciences. Her research focuses on the diagnostic utility and application of various testing methods in dermatopathology, particularly in the context of skin neoplasms and inflammatory conditions. She has been involved in developing and evaluating appropriate use criteria for ancillary diagnostic testing in her field, contributing to new recommendations for clinical scenarios.
Dr. Shalin's work includes the molecular profiling of skin tumors, investigating genetic alterations such as fusions and mutations in entities like dermal melanocytic tumors and syringocystadenocarcinoma papilliferum. She also contributes to the understanding of immunologic aspects of skin diseases, including bullous dermatoses and their response to therapies. Her research group collaborates with colleagues within the University of Arkansas for Medical Sciences, including Megan S. Evans, Brian Koss, Kirk L. West, and Erin M. Taylor, with whom she has co-authored multiple publications.
With a career marked by significant scholarly output, Dr. Shalin has authored 149 publications and accumulated over 2,300 citations, evidenced by an h-index of 21. She is recognized as a highly cited researcher. Her recent work continues to address the diagnostic challenges and evolving understanding of cutaneous diseases, including the utility of direct immunofluorescence testing.
Metrics
- h-index: 21
- Publications: 149
- Citations: 2,372
Selected Publications
-
Generalized Petechial‐Purpuric Eruption in a Child: A Rare Presentation of Parvovirus <scp>B19</scp> Infection (2026)
-
Non-Neoplastic Disorders of the Skin (2025)
-
A network-based cross-sectional study of geographic access disparities to Medicare-participating dermatologists in the United States (2025)
-
Merkel Cell Carcinoma Arising in Combination With Basal Cell Carcinoma: A Rare Diagnosis and Potential Pitfall (2025)
-
Violaceous Nodules in an Infant With Noonan Syndrome: Challenge (2025)
-
Violaceous Nodules in an Infant With Noonan Syndrome: Answer (2025)
-
Noninfectious Inflammatory Disorders of the Vulva (Female Low Genital Tract) (2025)
-
Vulvar Melanocytic Lesions (2025)
-
Not a Cyst: When a Cyst Obscures a More Nefarious Process (2025)
-
Unilateral Pachydermodactyly in a Young Female: A Rare Diagnosis Requiring Novel Clinicopathological Correlation (2025)
-
Histopathologic Features in Urticaria and Urticarial Variants: Plasma Cells Should Be Rare (2025)
-
Noninfectious Inflammatory Disorders of the Vulva (Female Low Genital Tract) (2024)
-
Perineuriomatous Melanocytic Nevi: A Case Series of Four Cases (2024)
-
Incidental detection of non‐melanoma neoplasms in sentinel lymph node biopsy for melanoma staging: A retrospective case series (2024)
-
Malignant Cutaneous Neurocristic Hamartoma With Features of Melanoma: A Rare Entity (2024)
Grants & Funding
- Kinase Suppressor of ras: Function in the hippocampus NIH Principal Investigator
- Identification of Druggable Targets to Complement Melanoma Therapy NIH Co-Investigator
Collaboration Network
Top Collaborators
Megan S. Evans
University of Arkansas for Medical Sciences
6 shared publications
In database
- A Pink Pedal Plaque in an 8-Year-Old Boy
- Bilateral eyelid swelling as the presenting sign of subcutaneous sarcoidosis
- Unilateral Pachydermodactyly in a Young Female: A Rare Diagnosis Requiring Novel Clinicopathological Correlation
- Violaceous Nodules in an Infant With Noonan Syndrome: Answer
- Violaceous Nodules in an Infant With Noonan Syndrome: Challenge
Showing 5 of 6 shared publications
Michael Cho
5 shared publications
In database
- Sebaceous gland atrophy due to seborrheic dermatitis in a patient with alopecia: A potential pitfall
- Perineuriomatous Melanocytic Nevi: A Case Series of Four Cases
- Merkel Cell Carcinoma Arising in Combination With Basal Cell Carcinoma: A Rare Diagnosis and Potential Pitfall
- Noninfectious Inflammatory Disorders of the Vulva (Female Low Genital Tract)
- Noninfectious Inflammatory Disorders of the Vulva (Female Low Genital Tract)
May P. Chan
University of Michigan–Ann Arbor (US)
4 shared publications
- Deep Herpes
- Molecular Profiling of Syringocystadenocarcinoma Papilliferum Reveals <i>RAS</i> -Activating Mutations
- Multicenter Evaluation of Certainty and Reliability in Calciphylaxis Diagnosis Using a Digital Imaging Platform
- Non-Neoplastic Disorders of the Skin
Rosalynn M. Nazarian
Massachusetts General Hospital (US)
4 shared publications
- Deep Herpes
- Molecular Profiling of Syringocystadenocarcinoma Papilliferum Reveals <i>RAS</i> -Activating Mutations
- Multicenter Evaluation of Certainty and Reliability in Calciphylaxis Diagnosis Using a Digital Imaging Platform
- Non-Neoplastic Disorders of the Skin
Bradley D. Shields
4 shared publications
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
Brian Koss
4 shared publications
In database
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
Erin M. Taylor
4 shared publications
In database
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
Aaron J. Storey
4 shared publications
In database
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
Kirk L. West
4 shared publications
In database
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
Stephanie D. Byrum
4 shared publications
In database
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
Samuel G. Mackintosh
4 shared publications
In database
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
Rick Edmondson
4 shared publications
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
Fade Mahmoud
4 shared publications
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
Alan J. Tackett
4 shared publications
In database
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Supplementary Figure S1 from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
- Data from Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma
Katelynn Campbell
University of Saskatchewan (CA)
3 shared publications
- Immunologic overlap in a case of linear IgG/IgA bullous dermatosis responsive to rituximab
- Dermatofibrosarcoma protuberans with platelet‐derived growth factor‐D rearrangement; two cases with morphologically distinct presentations
- Vulvar Melanocytic Lesions
Similar Researchers
Based on overlapping research topics
Constantin Scharlach
Southern Arkansas University
Dermatology and Skin Diseases
Cancer Genomics and Diagnostics
Molecular Biology Techniques and Applications
Matthew V Steliga
University of Arkansas for Medical Sciences
Cancer Genomics and Diagnostics
Disease Mechanisms Research
Molecular Biology Techniques and Applications
J.T. Pilkington
University of Arkansas for Medical Sciences
Dermatology and Skin Diseases
Cancer Genomics and Diagnostics
Disease Mechanisms Research
Tara Akunna
University of Arkansas for Medical Sciences
Dermatology and Skin Diseases
Disease Mechanisms Research
Medical Case Studies
Meei Liu
University of Arkansas for Medical Sciences
Cancer Genomics and Diagnostics
Disease Mechanisms Research
Molecular Biology Techniques and Applications
Penelope Duerken-Hughes
National Center for Toxicological Research
Cancer Genomics and Diagnostics
Disease Mechanisms Research
Molecular Biology Techniques and Applications